Immunic Inc. (NASDAQ: IMUX) announced it will present additional data from its phase 2 CALLIPER trial of vidofludimus calcium at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE